Tom is Managing Director of Madeleine Pharmaceuticals.
has held positions in various start-ups, corporate management in Germany and on the stock market in the city of London.
Tom was previously a Venture Partner with Heidelberg Innovation following five years as a Senior Partner with Apax.
was involved with several of the larger transactions at Apax
including three corporate spin-outs.
In addition, his
extensive network resulted in his
securing several proprietary deals including Wilex, Zymogenitics, Metagen, BioImage and Atugen
acted as the primary team member on Genmab which returned over 500% IRR and is one of, if not, the top ranking healthcare transaction in the 25 year history of Apax
He was also founder of U3 Pharma which was subsequently sold to Daiichi Sankyo.
In 2008, Tom
moved at the invitation of the government to Australia as the Entrepreneur in Residence for Biotechnology in South Australia, co-founded Terra Rossa Capital
and subsequently progressed selected opportunities to companies, for example, Madeleine Pharmaceuticals
Tom has a degree in molecular biology (Honors) from University of Wisconsin at Madison and a PhD in veterinary science from Hannover, Germany.
He also holds a certification in veterinary anesthesiology from the Cornell University and an MBA from London Business School, where he was an international Rotary Scholar.